Vaccine against rsv

Abstract

Described is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype that comprises polynucleotide encoding a RSV F protein or immunologically active part thereof.

1 .- 16 . (canceled) 
     
     
         17 . A vaccine against respiratory syncytial virus (RSV), the vaccine comprising:
 a recombinant human adenovirus of serotype 35 that comprises a nucleic acid molecule encoding an RSV F protein or fragment thereof.   
     
     
         18 . The vaccine of  claim 17 , wherein the recombinant human adenovirus comprises a nucleic acid molecule encoding RSV F protein comprising SEQ ID NO: 1. 
     
     
         19 . The vaccine of  claim 17 , wherein the nucleic acid molecule encoding RSV F protein is codon optimized for expression in human cells. 
     
     
         20 . A vaccine against respiratory syncytial virus (RSV), the vaccine comprising:
 a recombinant human adenovirus of serotype 35 that comprises a nucleic acid molecule encoding an RSV F protein or fragment thereof, wherein the nucleic acid molecule encoding RSV F protein comprises SEQ ID NO: 2.   
     
     
         21 . The vaccine of  claim 17 , wherein the recombinant human adenovirus has:
 a deletion in the E1 region of the adenoviral genome,   a deletion in the E3 region of the adenoviral genome, or   a deletion in each of the E1 and the E3 regions of the adenoviral genome.   
     
     
         22 . The vaccine of  claim 17 , wherein the recombinant adenovirus has a genome comprising, at its 5′ terminal ends, the polynucleotide CTATCTAT. 
     
     
         23 . A method for vaccinating a subject against respiratory syncytial virus (RSV), the method comprising:
 administering to the subject the vaccine of  claim 17 .   
     
     
         24 . The method according to  claim 23 , wherein the vaccine is administered to the subject intramuscularly. 
     
     
         25 . The method according to  claim 23 , wherein the vaccine is administered to the subject more than once. 
     
     
         26 . The method according to  claim 23 , further comprising:
 administering to the subject a vaccine comprising a recombinant human adenovirus of serotype 35 comprising a nucleic acid molecule encoding an RSV F protein or fragment thereof.   
     
     
         27 . The method according to  claim 23 , consisting of a single administration of the vaccine to the subject. 
     
     
         28 . The method according to  claim 23 , further comprising:
 administering RSV F protein to the subject.   
     
     
         29 . A method for reducing infection and/or replication of respiratory syncytial virus (RSV) in a subject, the method comprising:
 administering to the subject by intramuscular injection a composition comprising a recombinant human adenovirus of serotype 35 comprising a nucleic acid molecule encoding an RSV F protein or fragment thereof.   
     
     
         30 . An isolated host cell comprising:
 a recombinant human adenovirus of serotype 35 that comprises a nucleic acid molecule encoding an respiratory syncytial virus (RSV) F protein or fragment thereof.   
     
     
         31 . A method for making a vaccine against respiratory syncytial virus (RSV), the method comprising:
 providing a recombinant human adenovirus of serotype 35 that comprises a nucleic acid molecule encoding an RSV F protein or fragment thereof,   propagating said recombinant human adenovirus in a culture of host cells, isolating and purifying the recombinant human adenovirus, and   formulating the recombinant human adenovirus into a pharmaceutically acceptable composition, which is a vaccine against RSV.   
     
     
         32 . A recombinant polynucleotide that forms a human adenovirus of serotype 35 genome, which genome comprises a nucleic acid molecule encoding an respiratory syncytial virus (RSV) F protein or fragment thereof. 
     
     
         33 . A vaccine against respiratory syncytial virus (RSV), the vaccine comprising:
 a recombinant human adenovirus of serotype 35 that comprises a polynucleotide encoding a fragment of an RSV F protein, wherein the polynucleotide encoding RSV F protein comprises SEQ ID NO: 2.   
     
     
         34 . A vaccine against respiratory syncytial virus (RSV), the vaccine comprising:
 a recombinant human adenovirus of serotype 35 that comprises a polynucleotide encoding a fragment of a respiratory syncytial virus (RSV) F protein, wherein the polynucleotide encoding RSV F protein comprises SEQ ID NO: 2, and   wherein the recombinant human adenovirus has:   a deletion in the E1 region of the adenoviral genome,   a deletion in the E3 region of the adenoviral genome, or   a deletion in each of the E1 and the E3 regions of the adenoviral genome.   
     
     
         35 . A method for vaccinating a subject against respiratory syncytial virus (RSV), the method comprising:
 administering to the subject the vaccine of  claim 34 .